Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Abemaciclib Active in HR+/HER2- Breast Cancer Patients With Brain Mets

June 28th 2017

Preliminary evidence suggests that abemaciclib penetrated brain metastases and had antitumor activity in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Study Offers Insight Into Age-Specific Breast, Ovarian Cancer Risk for BRCA-Positive Women

June 27th 2017

Researchers have yet to determine the degree to which harboring a BRCA1 or BRCA2 mutation raises a woman’s lifetime risk of developing breast and ovarian cancer.

Weight Loss Program Aims to Pinpoint Role of Obesity in Breast Cancer

June 27th 2017

Jennifer Ligibel, MD, describes the BWEL trial and the possible impact of weight loss intervention for patients with breast cancer.

Ribociclib Recommended for EU Approval in Frontline HR+/HER2- Breast Cancer

June 23rd 2017

The Committee for Medicinal Products for Human Use, a part of the European Medicines Agency, recommended approval of ribociclib (Kisqali) for use in combination with an aromatase inhibitor as a first-line treatment for postmenopausal women with hormone receptor-positive /HER2-negative locally advanced or metastatic breast cancer.

Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

June 23rd 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer

June 20th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.

Dr. Freedman on Preventing Brain Metastases in HER2+ Breast Cancer

June 20th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses preventing brain metastases in patients with HER2-positive breast cancer.

Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer

June 19th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

Evolving Therapies in HR+ Metastatic Breast Cancer

June 16th 2017

Options With CDK4/6 in HR+ Metastatic Breast Cancer

June 16th 2017

Final Thoughts on Progress in Breast Cancer Research

June 16th 2017

Immunotherapy for Triple-Negative Breast Cancer

June 16th 2017

PARP Inhibitors for BRCA-Mutated TNBC

June 16th 2017

BRCA-Mutated Triple-Negative Breast Cancer

June 16th 2017

Metastatic Triple-Negative Breast Cancer

June 16th 2017

Brain Metastases in HER2-Positive Breast Cancer

June 16th 2017

Triple-Positive Metastatic Breast Cancer

June 16th 2017

Adjuvant Therapy for High-Risk HER2+ Breast Cancer

June 16th 2017

Pending FDA Approval of Neratinib in HER2+ Breast Cancer

June 16th 2017

APHINITY Trial in HER2+ Breast Cancer

June 16th 2017